Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

hile demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR inhibitor, in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in advanced preclinical development.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts:Susan M. Kanaya

Burns McClellanSenior Vice President, Finance and

Media InquiriesChief Financial Officer or

Kathy Nugent, Ph.D.Markus J. Cappel, Ph.D.

212-213-0006Chief Business Officer

knugent@burnsmc.com650-210-2900investor@chemocentryx.com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic cancers and women,s health, has appointed Holly ... Managed Markets. Ms. Bauzon has a proven ... payer coverage for laboratory services companies. She has more ... PerkinElmer, Inc., where she held the position of Director, ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ... company, announced today that it has completed integration ... solution for Plastic Surgery and Dermatology practices. ... more value to healthcare practices using Nextech," stated ... eRelevance Corporation. "Using information from the EMR we ...
(Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... A new study finds a wide range of ... related to key environmental exposuresin children with Crohn,s disease (CD), ... of the Crohn,s & Colitis Foundation of America ... & Wilkins , a part of Wolters Kluwer Health ... alterations of DNA in several regions of the genome in ...
(Date:8/22/2014)... images of nurses at New York University,s Langone Medical ... many including the youngest and most vulnerable down flights ... storm surge generated by Hurricane Sandy. , Now, ... University Colleges of Nursing (NYUCN) and of Dentistry (NYUCD), ... examines the impact on NYULMC nurses, post-Sandy deployment to ...
(Date:8/22/2014)... Oldsmar, FL (PRWEB) August 22, 2014 ... Cryo-Cell’s cell therapy research affiliate, Saneron CCEL Therapeutics, Inc. ... agreement. , “Cryo-Cell is extremely pleased to collaborate with ... an IND, which we hope will lead to regenerative ... neurodegenerative diseases such as ALS,” David Portnoy, Chairman and ...
(Date:8/22/2014)... News) -- The U.S. Drug Enforcement Administration (DEA) is ... hydrocodone, which has been tied to a surge in ... restrictions would cover prescription narcotic drugs such as Vicodin, ... same regulatory class as painkillers such as Oxycontin, Percocet ... a three-month supply of the drug and will have ...
Breaking Medicine News(10 mins):Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 2Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 3
... - New Hayfever Relief Product Based on Acupressure ... , - With Photo , ... it,s believed that,it now affects as many as 1 in 4 ... either complete misery with symptoms such as reduced,concentration, runny nose and ...
... Improvement Firm Recognizes Efforts in Patient SatisfactionSOUTH BEND, Ind., ... Press Ganey Associates, Inc., is proud to recognize all ... improving the quality of care they provide."The doctors, nurses, ... to improve quality, and they deserve to be commended," ...
... urged to prevent head, neck injuries , , SUNDAY, May ... help prevent head and neck injuries related to recreational ... year in the United States, about 1.5 million people ... and nearly 12,000 are treated for neck fractures, according ...
... Support the Nancy Davis Foundation for Multiple Sclerosis LOS ... the world,s most exclusive super sport cars, donated the ... to support the Nancy Davis Foundation for Multiple Sclerosis ... charity event at the Hyatt Regency Century Plaza in ...
... thwart hospital ,superbugs, viruses and mold, scientists say ... paint kills disease-causing bacteria, mold, fungi and viruses, said ... claim their paint, which can be used in homes, ... so-called "superbugs," antibiotic-resistant microbes that are found in hospitals ...
... free workshops with an emphasis on smoking cessation to raise public ... in order to improve their quality of life. , ... ... consecutive year, May 2009 has been designated Stroke Awareness Month. During ...
Cached Medicine News:Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 2Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 3Health News:Press Ganey Supports National Hospital Week 2Health News:Press Ganey Supports National Hospital Week 3Health News:Ladders, Swings and More Can Cause Peril 2Health News:First U.S. Lamborghini Gallardo LP 560-4 Spyder Auctioned at Race to Erase MS Charity Event 2Health News:Health Care Professionals Offer Free Consultations for National Stroke Awareness Month 2
... Medical is the world leader in ... used worldwide for permanent pacemaker and ... and port implantation, and for temporary ... St. Jude Medical Peel-Away introducers includes ...
... Self-Expanding Stent System combines low-profile, high radial force, ... guide wire compatible stent system provides 6F sheath ... (5.0 - 10.0 mm). Now, with longer stents ... five stent lengths (28, 38, 56, 80 and ...
... A particular challenge in transseptal left heart ... must be exchanged for a sheath with ... wall position. Traditionally, such an exchange has ... heparinized patient. Biosense Webster has overcome this ...
Coaxial Multicolor LIO Worlds first coaxial multicolor LIO provides precise laser delivery with repeatable outcomes, as well as maximum treatment options and physician safety....
Medicine Products: